Our in vitro studies with AC-16 cardiomyocytes demonstrated that CXCR4 antagonist AMD3100 could block the hyperglycemia mediated increase in TGFβ similar to the GLC mediated reduction. This evidence concerns the gene CXCR4 and Hyperglycemia.